However, for patients undergoing alloHSCT in CR, there was a highly significant difference in OS between pre-transplant MRD-negative and MRD-positive cases, with estimated 5-year OS rates of 89% versus 40%, respectively.
← all excerpts
Minimal/Measurable Residual Disease Monitoring in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.
1
—
—